Consequently, we examine how targeting the inhibition of IL-25, IL-33 and type 2 intestinal immunity, to release the brakes on type 1 anti-cancer immunity, may be beneficial in certain CRC subtypes, but detrimental in others. The gene discussed is IL25; the disease is cancer.